CD8A and metastatic melanoma: Further, the 6-month clinical response to an ICI (pembrolizumab or ipilimumab plus nivolumab combination therapy) was associated with a large CD8+ T cell clone count 21 days after treatment, suggesting that post-ICI peripheral CD8+ clonality can provide information regarding the likely long-term treatment response in metastatic melanoma patients [13].